Envestnet Asset Management Inc. Sells 43,490 Shares of Bruker Corporation $BRKR

Envestnet Asset Management Inc. trimmed its holdings in shares of Bruker Corporation (NASDAQ:BRKR) by 13.9% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 269,919 shares of the medical research company’s stock after selling 43,490 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Bruker were worth $8,770,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in BRKR. Royal Bank of Canada lifted its holdings in shares of Bruker by 8.3% during the 1st quarter. Royal Bank of Canada now owns 123,336 shares of the medical research company’s stock valued at $5,148,000 after purchasing an additional 9,501 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in Bruker during the first quarter worth about $262,000. Goldman Sachs Group Inc. lifted its stake in shares of Bruker by 107.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,465,319 shares of the medical research company’s stock valued at $61,162,000 after purchasing an additional 758,301 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Bruker by 2.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 366,204 shares of the medical research company’s stock worth $15,285,000 after acquiring an additional 9,235 shares in the last quarter. Finally, Focus Partners Wealth grew its holdings in Bruker by 115.0% in the first quarter. Focus Partners Wealth now owns 11,232 shares of the medical research company’s stock valued at $469,000 after purchasing an additional 6,008 shares during the period. 79.52% of the stock is currently owned by institutional investors.

Bruker Trading Down 2.5%

BRKR opened at $38.76 on Friday. The firm has a market cap of $5.89 billion, a price-to-earnings ratio of -258.40, a price-to-earnings-growth ratio of 2.38 and a beta of 1.19. The business’s 50 day moving average is $46.29 and its two-hundred day moving average is $40.45. The company has a quick ratio of 0.87, a current ratio of 1.73 and a debt-to-equity ratio of 0.75. Bruker Corporation has a 52 week low of $28.53 and a 52 week high of $56.22.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Thursday, February 12th. The medical research company reported $0.59 EPS for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.06). The business had revenue of $977.20 million during the quarter, compared to analyst estimates of $964.61 million. Bruker had a negative net margin of 0.25% and a positive return on equity of 13.56%. The company’s revenue for the quarter was down .2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.76 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, research analysts predict that Bruker Corporation will post 2.69 EPS for the current year.

Analyst Upgrades and Downgrades

BRKR has been the topic of a number of research reports. TD Cowen decreased their price target on shares of Bruker from $53.00 to $43.00 and set a “hold” rating on the stock in a research note on Friday, February 13th. Jefferies Financial Group set a $50.00 price objective on Bruker in a report on Thursday, February 12th. UBS Group reiterated a “neutral” rating and set a $49.00 price target on shares of Bruker in a research report on Friday, February 13th. Wolfe Research upgraded Bruker from a “peer perform” rating to an “outperform” rating and set a $60.00 target price for the company in a report on Wednesday, December 10th. Finally, JPMorgan Chase & Co. increased their price objective on Bruker from $50.00 to $55.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $50.38.

Insider Activity

In other news, VP Mark Munch sold 7,000 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $55.00, for a total value of $385,000.00. Following the transaction, the vice president owned 128,443 shares of the company’s stock, valued at approximately $7,064,365. The trade was a 5.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 27.30% of the company’s stock.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.